

03 May 2024 | Analysis

Pink Sheet Podcast: US FDA Adcomm Reform, Clinical Trial Modeling Boost, AI For Drug Review

by **Pink Sheet Team**

Pink Sheet reporter and editors discuss what an upcoming listening session means for the FDA's advisory committee reform effort, the agency's efforts to help clinical trial modeling and simulation, and the UK's MHRA plan to use artificial intelligence to assist in drug reviews.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Eliza Slawther, Senior Editor Sue Sutter and Editor in Chief Nielsen Hobbs consider why the US Food and Drug Administration what an upcoming listening session means for the pace of advisory committee reform (:32), the potential impact of the agency's Model Master File idea on the pharmaceutical industry (16:22), and what the UK Medicines and Healthcare products Regulatory Agency (MHRA)'s use of artificial intelligence in drug review could mean for sponsors (21:05).

[Click here to explore this interactive content online](#) ✨

More On These Topics From The Pink Sheet

- [US FDA Adcomm Reform: Does Listening Session Suggest No Major Near-Term Changes?](#)
- [US FDA Wants Advice About Advisory Committees: Try Having Some?](#)
- [US FDA Developing Model Master File System To Grow Modeling, Simulation Field](#)
- [UK's MHRA To Use AI In Regulatory Review Process & RWD Analysis](#)

This and other podcasts are available on the *Pink Sheet* [podcast page](#), as well as the

Citeline channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.